Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Novelion (NVLN.TO)

Novelion (NVLN.TO)

0.00
-0.00 (0.00%)
52 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
TOP PICK

Novelion(NVLN.TO)

Sep 23, 2003
One trick pony however, they do have some tremendous potential for expansion of their Visodine product. Also expecting approval for funding for more expanded use of their product.
Photo of Ted MacklinTed Macklin
Owned
Unlock Rating
$23.50

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Sep 19, 2003
Has a very difficult time breaking the $24 mark. Has had a lot of good news. Does not look cheap on earnings basis. Could still have failure at the FDA trials. Risky.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$23.29

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Novelion(NVLN.TO)

Sep 18, 2003
(A top pick Aug 6/03. Up 3%.) Still likes.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$24.19

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Sep 17, 2003
OK to buy the long-term. Should be a terrific performer in the next 2/3 years.
Photo of Peter BriegerPeter BriegerUnlock Rating
$22.53

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Aug 19, 2003
A news driven stock.This sector is volatile, but this company has product and makes money.A pretty good company, but buy on the dips.
Photo of David BaskinDavid BaskinUnlock Rating
$19.30

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Aug 19, 2003
Should be able to move higher.Earnings should continue to grow.Could be a takeover.
Photo of Mike WeirMike Weir
Owned
Unlock Rating
$19.30

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Aug 18, 2003
It has demographics going for it.Visodine sales are ramping up a little.The easy money has been made.Starting to look a little bit expensive.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$19.45

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Aug 15, 2003
Believes there are several catalysts in the next few months that potentially could make the shares move to a price level that would be higher than merited by their existing business.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$19.82

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Aug 11, 2003
Had a good run.Would like to buy it a dollar or two cheaper.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$18.91

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Novelion(NVLN.TO)

Aug 06, 2003
They are finding more and more uses for their product.Could be used in cancer treatment.World-class technology.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$21.92

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Novelion(NVLN.TO)

Jul 28, 2003
Looking better. Fundamentals are good. Profitable.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$23.92

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Jul 21, 2003
Nice base pattern. Could be a little higher a year from now.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$18.65

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Jun 19, 2003
Still has some good upside potential.
Photo of Ray SteeleRay SteeleUnlock Rating
$17.63

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Jun 10, 2003
Was extremely cheap in the $11/12 range, but feels $17/18 may be a little high. Would like to see a pull back.
Photo of Mark Jackson, CFAMark Jackson, CFA
No
Unlock Rating
$18.95

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Jun 10, 2003
Great product. Should be able to expand its one product or will be taken over. Good shape financially.
Photo of Nereo PiticcoNereo PiticcoUnlock Rating
$18.95

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 61 to 75 of 190 entries
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica